Breaking News

U.S. Says 72-Hour Cease-Fire Agreed in Gaza, to Start Tomorrow
Tweet TWEET

NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014

  NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for
                              February 19, 2014

PR Newswire

FORT MYERS, Fla., Jan. 17, 2014

FORT MYERS, Fla., Jan. 17, 2014 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO) announced today that it plans to release its fourth quarter 2013 and full
year 2013 financial results on Wednesday, February 19, 2014.

The Company has scheduled a web-cast and conference call to discuss their Q4
2013 and full year 2013 results on Wednesday, February 19, 2014 at 11:00 AM
EST. Interested investors should dial (877) 407-8035 (domestic) and (201)
689-8035 (international) at least five minutes prior to the call and ask for
Conference ID Number 13574927. A replay of the conference call will be
available until 11:59 PM on March 5, 2014 and can be accessed by dialing (877)
660-6853 (domestic) and (201) 612-7415 (international). The playback
conference ID Number is 13574927. The web-cast may be accessed under the
Investor Relations section of our website at www.neogenomics.com or
http://www.investorcalendar.com/IC/CEPage.asp?ID=172163. An archive of the
web-cast will be available until 11:59 PM on May 19, 2014.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that
specializes in cancer genetics diagnostic testing, the fastest growing segment
of the laboratory industry. The company's testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, anatomic pathology and molecular genetic testing.

Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,
Irvine, CA, Tampa and Fort Myers, FL. NeoGenomics services the needs of
pathologists, oncologists, other clinicians and hospitals throughout the
United States. For additional information about NeoGenomics, visit
http://www.neogenomics.com.

Interested parties can also access investor relations material from Hawk
Associates at http://www.hawkassociates.com or neogenomics@hawk.com and from
Zack's Investment Research at http://www.zacks.com or scr@zacks.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements, Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.

For further information, please contact:

NeoGenomics, Inc.              Hawk Associates, Inc.
Steven C. Jones                Ms. Julie Marshall
Director of Investor Relations (305) 451-1888
(239) 325-2001                 neogenomics@hawkassociates.com
sjones@neogenomics.com

SOURCE NeoGenomics, Inc.

Website: http://www.neogenomics.com